UK’s GHO acquires DEL-based discovery services provider X-Chem
Category: #healthcare  By Mateen Dalal  Date: 2020-06-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

UK’s GHO acquires DEL-based discovery services provider X-Chem

Matt Clark, Senior VP of Chemistry and X-Chem Co-Founder, would be named as the new company CEO

London-based healthcare investment adviser, Global Healthcare Opportunities (GHO) Capital has recently announced that it has acquired leading DNA-Encoded Library (DEL)-based discovery service provider, X-Chem Inc. from an affiliate of Hellman & Friedman LLC and The Carlyle Group.

With the help of its proprietary DEL platform that has libraries consisting of over 200 billion small molecules, X-Chem offers drug discovery services to numerous biopharma partners. It has licensed more than seventy research programs including multiple novel chemical entities, to firms throughout Europe, Japan, and the US.

As per the agreement, Matt Clark, current SVP of Chemistry and X-Chem’s co-founder, would be named as the new CEO of the unit. Being a thought leader in DEL-mediated hit identification and drug discovery, Matt would be an ideal fit for leading X-Chem to its next phase of development.

Reportedly, Matt would replace Rick Wagner, X-Chem’s co-founder and previous CEO, who will be resigning from the firm. While the company was under Rick’s leadership, it managed to scale itself from a niche discovery platform to a prominent novel drug leads provider.

X-Chem would gain significant benefits from GHO’s global network, international resources, and deep expertise to boost its expansion plans. With constant support and investment from GHO, the company would be able to develop best-in-class solutions.

Speaking on the move, Rick Wagner, said that the company would like to thank Hellman & Friedman and Carlyle for their continuous support and partnership, helping X-Chem reach the position of industry leadership.

Matt has played an integral role in advancing their company to the peaks of DEL technology, and he will further ensure that the company reaches to the next level. 

Source: https://ghocapital.com/gho-capital-acquires-x-chem-a-leading-drug-discovery-service-provider/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Novartis reveals data from Phase III COMBI-i trial for melanoma
Novartis reveals data from Phase III COMBI-i trial for melanoma
By Mateen Dalal

Swiss-based multinational pharmaceutical company, Novartis has recently revealed detailed results fr...

Curevo declares antibody response data from Phase 1 study of CRV-101
Curevo declares antibody response data from Phase 1 study of CRV-101
By Mateen Dalal

Biopharmaceutical major, Curevo Vaccine, has reportedly announced the release of antibody response d...

CATO SMS announces acquisition of Wilmington-based Array Biostatistics
CATO SMS announces acquisition of Wilmington-based Array Biostatistics
By Mateen Dalal

CATO SMS, one of the leading providers of specialized clinical research solutions, has reportedly ac...